Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Kyntra Bio clinical trials
Also known as FibroGen.
The registry lists 41 studies whose lead sponsor is Kyntra Bio. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 17, 2026.
Keep track of what changes. Save the Kyntra Bio studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Kyntra Bio.
- FibroGen39 studiesSame company
Something wrong?
- Kyntra Bio2 studiesSame company
Something wrong?
Focus areas
Conditions Kyntra Bio leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 41 of 41.
- A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingNCT06842498Phase 2
- A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)Not yet recruitingNCT07722988Phase 3
- Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT03941093Phase 3
Sponsor listed in the registry: FibroGen
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Phase 3
Sponsor listed in the registry: FibroGen
- Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)TerminatedNCT02606136Phase 2
Sponsor listed in the registry: FibroGen
- Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedNCT04632940Phase 3
Sponsor listed in the registry: FibroGen
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Phase 3
Sponsor listed in the registry: FibroGen
- Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenTerminatedNCT03263091Phase 3
Sponsor listed in the registry: FibroGen
- Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)TerminatedNCT04371666Phase 3
Sponsor listed in the registry: FibroGen
- Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary FibrosisCompletedNCT00074698Phase 1
Sponsor listed in the registry: FibroGen
- A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid MalignanciesCompletedNCT05301517Phase 3
Sponsor listed in the registry: FibroGen
- Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)CompletedNCT03303066Phase 2/3
Sponsor listed in the registry: FibroGen
- A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT02210559Phase 1/2
Sponsor listed in the registry: FibroGen
- Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis ParticipantsCompletedNCT04410198Phase 3
Sponsor listed in the registry: FibroGen
- Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis ParticipantsCompletedNCT04484857Phase 3
Sponsor listed in the registry: FibroGen
- Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 DiseaseTerminatedNCT04432298Phase 2
Sponsor listed in the registry: FibroGen
- Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDWithdrawnNCT04621331Phase 3
Sponsor listed in the registry: FibroGen
- Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaCompletedNCT04076943Phase 2
Sponsor listed in the registry: FibroGen
- Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney DiseaseCompletedNCT04059913Phase 4
Sponsor listed in the registry: FibroGen
- Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With AnemiaCompletedNCT01244763Phase 2
Sponsor listed in the registry: FibroGen
- Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisCompletedNCT01147666Phase 2
Sponsor listed in the registry: FibroGen
- Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring DialysisCompletedNCT00761657Phase 2
Sponsor listed in the registry: FibroGen
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisCompletedNCT02273726Phase 3
Sponsor listed in the registry: FibroGen
- Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney DiseaseCompletedNCT01630889Phase 2
Sponsor listed in the registry: FibroGen
- Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis ParticipantsCompletedNCT02052310Phase 3
Sponsor listed in the registry: FibroGen
- A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisCompletedNCT01750190Phase 3
Sponsor listed in the registry: FibroGen
- Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent TreatmentCompletedNCT01414075Phase 2
Sponsor listed in the registry: FibroGen
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01890265Phase 2
Sponsor listed in the registry: FibroGen
- Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary FibrosisCompletedNCT01262001Phase 2
Sponsor listed in the registry: FibroGen
- Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic NephropathyCompletedNCT00754143Phase 1
Sponsor listed in the registry: FibroGen
- Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)TerminatedNCT00782561Phase 1
Sponsor listed in the registry: FibroGen
- Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB TherapyTerminatedNCT00913393Phase 2
Sponsor listed in the registry: FibroGen
- FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on DialysisCompletedNCT02652819Phase 3
Sponsor listed in the registry: FibroGen
- FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney DiseaseCompletedNCT02652806Phase 3
Sponsor listed in the registry: FibroGen
- A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B InfectionTerminatedNCT01217632Phase 2
Sponsor listed in the registry: FibroGen
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01181245Phase 1
Sponsor listed in the registry: FibroGen
- Study of FG-4592 in Subjects With Chronic Kidney Disease in ChinaCompletedNCT01599507Phase 2
Sponsor listed in the registry: FibroGen
- Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in ChinaCompletedNCT01596855Phase 2
Sponsor listed in the registry: FibroGen
- Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult SubjectsCompletedNCT01376063Phase 1
Sponsor listed in the registry: FibroGen
- Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes MellitusCompletedNCT00102297Phase 1
Sponsor listed in the registry: FibroGen
- A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human ErythropoietinCompletedNCT00456053Phase 2
Sponsor listed in the registry: FibroGen